The in vitro activity of S-6123, a synthetic antimicrobial compound of the new oxazolidinone series, was compared with those of other orally administered agents against 328 clinical isolates. The (Fig. 1) .
The oxazolidinone compounds are recently developed, oral, synthetic antibacterial compounds unrelated to any other known antibacterial agents of natural or synthetic origin. Among those synthesized are S-6123, the first compound available, DuP 105, and DuP 721 (3). S-6123 has the structure (R)-4[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-benzene sulfonamide (Fig. 1) .
In this study, we describe the in vitro antibacterial spectrum of S-6123 in comparison with currently available oral antibacterial agents and the in vivo activity of the compound in a lethal peritonitis model in the rat. The mechanism of antibacterial action of S-6123 was explored by examining its effects on the syntheses of DNA, RNA, and protein in whole cells and on polypeptide synthesis in isolated bacterial ribosomes.
(This work was presented in part at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy [J. S. Daly, G. M. Eliopoulos, S. Willey, and R. C. Moellering, Jr., Program Abstr. 27th Intersci. Conf. Antimicrob. Agents Chemother. abstr. no. 248, 1987] .) MATERIALS AND METHODS Organisms. Bacterial strains used in this study were unique clinical isolates collected at the New England Deaconess and Massachusetts General Hospitals, Boston, Mass., with the exceptions of the penicillin-resistant pneumococci and viridans group streptococci, which had been collected in South Africa (4, 6) .
Antimicrobial agents and chemicals. Standard antimicrobial reference powders were obtained from the following sources: S-6123, E. I. Agar dilution susceptibility studies. Susceptibility testing was performed by a standard agar dilution technique (11), using Mueller-Hinton agar (BBL Microbiology Systems, Cockeysville, Md.), which was supplemented with 5% defibrinated sheep blood when nonenterococcal streptococci were tested or IsoVitaleX (BBL) and 5% chocolatized horse blood for testing Haemophilus influenzae. Inocula of approximately 104 CFU were applied to plates with a 32-prong inoculating device. Inocula were prepared by appropriate dilution of overnight broth cultures (gram-negative bacilli) or suspensions prepared from fresh plates (gram-positive organisms and H. influenzae) in fresh Mueller-Hinton broth (BBL). Suspensions were standardized to a 0.5 McFarland standard before dilution. Inoculated plates were examined for growth after 18 to 20 h of incubation at 37°C in room air. Campylobacter jejuni were tested on brucella agar (Difco Laboratories, Detroit, Mich.) with 10% sheep blood, and plates were read after 24 h of incubation in a microaerophilic atmosphere (BBL). To evaluate effects of different media and supplements on the in vitro activity of S-6123, susceptibility studies against selected isolates were performed with dextrose phosphate broth (GIBCO Laboratories, Grand Island, N.Y.) plus 1.5% Bacto-agar (Difco) and MuellerHinton agar supplemented with 5% defibrinated sheep blood, horse blood, pooled human serum, rat serum, or thymidine phosphorylase (Burroughs Wellcome). Thymidine phosphorylase was added to examine whether thymidine in the media affected the in vitro activity of the new compound. Studies of protein synthesis in a cell-free system. The direct effect of S-6123 on protein synthesis, using ribosomes prepared from a clinical strain of Enterococcus faecalis, was assessed in a cell-free system by the method of Nirenberg (7) with minor modifications as described by Farber et al. (6 Co., Inc., Glenolden, Pa., and ampicillin levels were measured by using a Micrococcus luteus bioassay (1). Serum bactericidal activity against E. coli was determined by a standard method (9) .
RESULTS
Susceptibility studies. Results of agar dilution susceptibility studies are shown in Tables 1, 2 , and 3. S-6123 demonstrated greatest activity against nonenterococcal streptococci and H. influenzae, with MICs for 90% of the strains of 16 to 32 ,ug/ml. There was no significant difference in activity against the penicillin-resistant or penicillin-susceptible viridans streptococci, or the ,-lactamase-producing or non-plactamase-producing H. influenzae. Staphylococci were inhibited at concentrations between 8 and 64 ,g/ml. Enterococcus faecalis and E. coli were inhibited at concentrations of <128 pLg/ml, a level which may be achiev- able in the urine after oral dosing. Occasional strains of other gram-negative organisms were resistant to the drug at this concentration (Table 3) . Testing in dextrose phosphate broth agar or in Mueller-Hinton agar with supplemental sheep blood, horse blood, human serum, rat serum, or thymidine phosphorylase did not significantly alter MICs of S-6123 against five strains each of E. coli, Klebsiella pneumoniae, Enterobacter aerogenes, Staphylococcus aureus, Enterococcus faecalis, or viridans streptococci (data not shown). Against six strains of representative staphylococci and streptococci, MBCs exceeded broth dilution MICs by at least fourfold. In all instances, MBCs were >128 jig/ml.
There was no significant difference in the MIC of S-6123 against E. coli ATCC 25922 whether the compound was tested in minimal salts media with or without Ca2+ or Mg2+ or in Mueller-Hinton broth.
Selection of resistance. No resistant colonies of E. coli could be selected by stepwise passage on agar plates containing twofold incremental concentrations of S-6123. However, with serial passage on incremental concentrations of S-6123, colonies of Enterococcusfaecalis resistant to levels as high as 1,000 ,ug/ml could be selected. The faint haze of growth of Enterococcus faecalis which occurred at high concentrations of S-6123 required 72 h of incubation for detection, and the resulting colonies returned to base-line susceptibility after passage in drug-free agar. No resistant colonies were noted when a high inoculum of E. coli or Enterococcusfaecalis was applied to agar containing S-6123 at four times the MIC. (10) 128 >128
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Mechanism of action. Studies of macromolecular synthesis showed no direct effect of S-6123 on DNA or RNA synthesis, but marked inhibition of protein synthesis in E. coli (Fig.  2) . The effect of S-6123 on protein synthesis was similar to that seen with chloramphenicol (Fig. 3) . S-6123 at concentrations of 0.2 to 200 ,ug/ml caused a 33 to 75% decrease in poly(U)-directed synthesis of polyphenylalanine in the cellfree system (Fig. 4) .
Rat peritonitis model. The MICs of S-6123 and ampicillin against the strain of E. coli used in this model were 64 and 2.0 ,g/ml, respectively. Pharmacokinetic studies performed in the rats showed that peak serum concentrations of S-6123 occurred 60 to 120 min after oral dosing, and those of ampicillin occurred 30 min after oral dosing. Mean peak serum concentrations of S-6123 were 3.8 ,ug/ml at 1 h after the initial dose and 7.5 ,ug/ml at 1 h after the second oral dose. The mean peak concentration of ampicillin, 30 min after dosing, was 0.93 ,ug/ml, with concentrations of -0.17 ,ug/ml immediately prior to the second dose. Thus, the peak serum levels of both drugs in infected rats were less than the MIC of the drugs for the test organism. The average urinary concentration of S-6123 was 169 p.g/ml in a 24-h urine specimen. Serum obtained from the animals at the time of peak drug concentrations had no in vitro bacteriostatic or bactericidal activity against E. coli. In addition, time-kill studies showed that there was no in vitro bactericidal activity of the drug at concentrations of 16 to 64 ,ug/ml or at ampicillin concentrations of 0.5 to 2.0 ,ug/ml against the test strain.
Twenty-three rats were given S-6123 and 21 animals received ampicillin, while 23 animals served as untreated controls. Thirteen percent (3 of 23) of the S-6123-treated, 20% (6 of 21) of the ampicillin-treated, and 96% (22 of 23) of the control animals were dead at 48 h. The differences were statistically significant between S-6123 and control (X2 = 28.39; P < 0.05) and between ampicillin and control (X2 = 18.5; P < 0.05), but there was no statistically significant difference between S-6123 and ampicillin (X2 = 0.812). All surviving animals examined in both treatment and control groups showed the presence of large intraabdominal abscesses on the intraperitoneal surface at 3 weeks after inoculation despite the lack of apparent morbidity. The abscesses grew E. coli in pure culture.
DISCUSSION
The oxazolidinone, S-6123, is an early representative of a new series of antimicrobial agents. This agent was found to have greatest in vitro activity against streptococci and staphylococci, Inhibition of enterococci and E. coli required somewhat higher concentrations, while other gram-negative bacilli appeared to be relatively resistant to the drug. Although actual levels attainable in humans are still incompletely defined, animal studies suggest that the more susceptible of these organisms would be inhibited by concentrations of the drug achievable in the urine after oral administration.
Susceptibility to the compound did not appear to correlate with susceptibility to comparative agents within any species studied. While it was possible to select for resistance to the drug in enterococci by repetitive passage on increasing concentrations of the compound, this resistance was unstable after passage on antimicrobial agent-free media. This, together with the fact that detection frequencies for spontaneous resistance to fourfold the MIC of the drug were <10-9, suggests that emergence of drug resistance during therapy would not likely be a major problem.
The new drug demonstrated only bacteriostatic activity against representative gram-positive isolates. On the basis of studies in both whole cells and cell-free systems, the antimicrobial effect of the drug was found to be exerted primarily through inhibition of protein synthesis. Attempts to isolate a resistant mutant to pinpoint the ribosomal subunit specificity of the compound were unsuccessful. Studying another representative of the oxazolidinone class of new antimicrobial agents, Eustice et al. (5) have also shown this drug to inhibit protein synthesis in Bacillus subtilis. Using a series of mutants with known resistance markers at specific target levels, these authors concluded that the action of the drug occurs at a target prior to chain elongation.
Of great interest was the observation that serum concentrations of S-6123 equivalent to one-tenth the MIC for the infecting strain of E. coli substantially reduced mortality in a rat model of lethal peritonitis. Reasons for this discrepancy between in vitro and in vivo effects are unknown, but do not appear due to medium dependency of susceptibility determinations. A similar discrepancy occurred in the ampicillin group. These results indicate that the new drug does possess in vivo activity that is worthwhile to pursue.
A number of compounds in this series are orally administered and excreted in the urine in animals, suggesting that they may be useful in the treatment of urinary tract infections. Even if S-6123 does not prove useful for human therapeutic purposes, it is representative of a new class of antimicrobial agents that shows a great deal of promise. Further studies with S-6123 and its analogs will be of great interest.
